and recommendation
Stemline Therapeutics, Inc. (STML)
Stemline Therapeutics (STML) a clinical-stage biopharmaceutical company, focuses on the discovering, acquiring, developing, and commercialization of proprietary oncology therapeutics.
STML develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which is in Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm, myeloproliferative neoplasms, and acute myeloid leukemia; and in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma. It also develops SL-801, a novel oral small molecule reversible inhibitor of a tumor-promoting nuclear transport protein, which is in Phase I clinical trial for the treatment of solid and hematologic cancers; and SL-701, an immunotherapy that is in Phase II clinical trial to attack brain cancer.
STML also develops SL-501, a next generation IL-3R-targeted therapy that is in preclinical development.
Stemline Therapeutics, Inc. was founded in 2003 and is based in New York, New York.
- June 19, 2014 - 9:17am | Out and About, Research Notes
- May 20, 2014 - 12:04pm | Research Notes
- May 17, 2014 - 1:31pm | Earnings, Earnings Q1
- May 17, 2014 - 1:27pm | Earnings
- May 1, 2014 - 12:32pm | BOD & C-Suite Updates
- April 8, 2014 - 10:07am | Regulatory
- April 4, 2014 - 9:30am | Research Notes
- April 1, 2014 - 10:53am | Regulatory
- March 11, 2014 - 10:45pm | Earnings, Earnings Q4
- February 23, 2014 - 3:20pm
- December 12, 2013 - 11:31am | BOD & C-Suite Updates
- November 25, 2013 - 8:25am | Regulatory
- November 16, 2013 - 6:54pm | Research Notes
- November 16, 2013 - 6:39pm | Research Notes
- October 29, 2013 - 8:42am | Research Notes
- October 18, 2013 - 12:05pm | Research Notes
- September 25, 2013 - 8:54am | Research Notes
- September 16, 2013 - 5:49pm | Research Notes
- July 23, 2013 - 8:10am | Research Notes
- July 1, 2013 - 7:02pm | Out and About